Ivan D Montoya

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi Drugs of abuse: management of intoxication and antidotes
    Ivan D Montoya
    Division of Pharmacotherapies and Medical Consequences of Drug Abuse, National Institute on Drug Abuse NIDA, National Institutes of Health NIH, Bethesda, MD 20892, USA
    EXS 100:519-41. 2010
  2. ncbi Influence of psychotherapy attendance on buprenorphine treatment outcome
    Ivan D Montoya
    Division of Pharmacotherapies and Medical Consequences of Drug Abuse, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Rockville, MD 20892, USA
    J Subst Abuse Treat 28:247-54. 2005
  3. ncbi Advances in the development of biologics to treat drug addictions and overdose
    Ivan D Montoya
    Division of Pharmacotherapies and Medical Consequences of Drug Abuse, National Institute on Drug Abuse, USA
    Adicciones 24:95-103. 2012
  4. ncbi Demographic and practice characteristics of psychiatrists who primarily treat patients with substance use disorders
    Ivan D Montoya
    Division of Treatment Research and Development, National Institute on Drug Abuse, Bethesda, MD 20892, USA
    Am J Addict 12:181-92. 2003
  5. ncbi Identification and treatment of patients with nicotine problems in routine clinical psychiatry practice
    Ivan D Montoya
    National Institute on Drug Abuse, Division of Pharmacotherapies and Medical Consequences of Drug Abuse, 6001 Executive Blvd, Bethesda, MD 20892 9551, USA
    Am J Addict 14:441-54. 2005
  6. ncbi Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence
    Ivan D Montoya
    Division of Treatment Research and Development and Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Baltimore, MD 21224, USA
    Clin Pharmacol Ther 75:34-48. 2004
  7. ncbi Novel medications to treat addictive disorders
    Ivan D Montoya
    Division of Pharmacotherapies and Medical Consequences of Drug Abuse, National Institute on Drug Abuse, National Institutes of Health, 6001 Executive Boulevard, Room 4143, Bethesda, MD 20892 9551, USA
    Curr Psychiatry Rep 10:392-8. 2008
  8. ncbi Open-label pilot study of bupropion plus bromocriptine for treatment of cocaine dependence
    Ivan D Montoya
    Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD 21224, USA
    Am J Drug Alcohol Abuse 28:189-96. 2002

Detail Information

Publications8

  1. ncbi Drugs of abuse: management of intoxication and antidotes
    Ivan D Montoya
    Division of Pharmacotherapies and Medical Consequences of Drug Abuse, National Institute on Drug Abuse NIDA, National Institutes of Health NIH, Bethesda, MD 20892, USA
    EXS 100:519-41. 2010
    ....
  2. ncbi Influence of psychotherapy attendance on buprenorphine treatment outcome
    Ivan D Montoya
    Division of Pharmacotherapies and Medical Consequences of Drug Abuse, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Rockville, MD 20892, USA
    J Subst Abuse Treat 28:247-54. 2005
    ..02). These results suggest that psychotherapy can improve the outcome of buprenorphine maintenance treatment for patients with dual (cocaine and opioid) dependence...
  3. ncbi Advances in the development of biologics to treat drug addictions and overdose
    Ivan D Montoya
    Division of Pharmacotherapies and Medical Consequences of Drug Abuse, National Institute on Drug Abuse, USA
    Adicciones 24:95-103. 2012
    ..The purpose of the article is to provide a general overview of the development of biologics for the treatment of drug addictions and overdose...
  4. ncbi Demographic and practice characteristics of psychiatrists who primarily treat patients with substance use disorders
    Ivan D Montoya
    Division of Treatment Research and Development, National Institute on Drug Abuse, Bethesda, MD 20892, USA
    Am J Addict 12:181-92. 2003
    ..The implications of these findings for psychiatry training programs and policy makers will be discussed...
  5. ncbi Identification and treatment of patients with nicotine problems in routine clinical psychiatry practice
    Ivan D Montoya
    National Institute on Drug Abuse, Division of Pharmacotherapies and Medical Consequences of Drug Abuse, 6001 Executive Blvd, Bethesda, MD 20892 9551, USA
    Am J Addict 14:441-54. 2005
    ....
  6. ncbi Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence
    Ivan D Montoya
    Division of Treatment Research and Development and Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Baltimore, MD 21224, USA
    Clin Pharmacol Ther 75:34-48. 2004
    ..CONCLUSIONS: A sublingual buprenorphine solution at 16 mg daily is well tolerated and effective in reducing concomitant opiate and cocaine use. The therapeutic effect on cocaine use appears independent of that on opiate use...
  7. ncbi Novel medications to treat addictive disorders
    Ivan D Montoya
    Division of Pharmacotherapies and Medical Consequences of Drug Abuse, National Institute on Drug Abuse, National Institutes of Health, 6001 Executive Boulevard, Room 4143, Bethesda, MD 20892 9551, USA
    Curr Psychiatry Rep 10:392-8. 2008
    ..This article reviews the current medications that are medically safe and have shown promising results for treating opioid, cocaine, methamphetamine, and cannabis addictions...
  8. ncbi Open-label pilot study of bupropion plus bromocriptine for treatment of cocaine dependence
    Ivan D Montoya
    Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD 21224, USA
    Am J Drug Alcohol Abuse 28:189-96. 2002
    ..There were no significant differences in outcome between groups. These results suggest that the combination of bupropion and bromocriptine is safe in cocaine addicts, but provide ambiguous evidence of its efficacy...